Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond
Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for treatment options in second-line and beyond for your patients with advanced renal cell carcinoma
Decera Clinical Education Oncology Podcast · Brian A. Costello MD, Martin H. Voss MD, Elizabeth R. Plimack MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:
• Treatment sequencing with IO and TKI therapies
• Optimizing dose for patients with preexisting toxicities
• Considerations for local control of metastatic sites
• Ongoing clinical trials
Presenters:
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York
Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.
Link to full program:
https://bit.ly/32IS9gx
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.